-
1
-
-
84974717508
-
Filoviridae: Marburg and Ebola viruses
-
Knipe D.M., Howley P.M., (eds), Philadelphia (PA): Lippincott Williams & Wilkins
-
H.Feldmann, A.Sanchez, T.W.Geisbert Filoviridae:Marburg and Ebola viruses. In:D.M.Knipe, P.M.Howley, editor. Fields virology. Philadelphia (PA):Lippincott Williams & Wilkins; 2013. p. 923–956.
-
(2013)
Fields virology
, pp. 923-956
-
-
Feldmann, H.1
Sanchez, A.2
Geisbert, T.W.3
-
2
-
-
0032566901
-
The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer
-
V.A.Volchkova, H.Feldmann, H.D.Klenk, et al. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology. 1998;250:408–414.
-
(1998)
Virology
, vol.250
, pp. 408-414
-
-
Volchkova, V.A.1
Feldmann, H.2
Klenk, H.D.3
-
3
-
-
79956064784
-
A new Ebola virus nonstructural glycoprotein expressed through RNA editing
-
M.Mehedi, D.Falzarano, J.Seebach, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011;85:5406–5414.
-
(2011)
J Virol
, vol.85
, pp. 5406-5414
-
-
Mehedi, M.1
Falzarano, D.2
Seebach, J.3
-
4
-
-
84991729160
-
Ebola virus disease – Democratic Republic of Congo
-
Geneva: WHO
-
WHO. Ebola virus disease – Democratic Republic of Congo. Disease Outbreak News. Geneva:WHO; 2014.
-
(2014)
Disease Outbreak News
-
-
-
5
-
-
0031688699
-
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
-
M.Bray, K.Davis, T.Geisbert, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1998;178:651–661.
-
(1998)
J Infect Dis
, vol.178
, pp. 651-661
-
-
Bray, M.1
Davis, K.2
Geisbert, T.3
-
6
-
-
0034993883
-
The role of the Type I interferon response in the resistance of mice to filovirus infection
-
M.Bray. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol. 2001;82:1365–1373.
-
(2001)
J Gen Virol
, vol.82
, pp. 1365-1373
-
-
Bray, M.1
-
7
-
-
0032993240
-
Pathogenesis of experimental Ebola virus infection in guinea pigs
-
B.M.Connolly, K.E.Steele, K.J.Davis, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999;179(Suppl 1):S203–S217.
-
(1999)
J Infect Dis
, vol.179
, pp. S203-S217
-
-
Connolly, B.M.1
Steele, K.E.2
Davis, K.J.3
-
8
-
-
84871768273
-
A Syrian golden hamster model recapitulating ebola hemorrhagic fever
-
H.Ebihara, M.Zivcec, D.Gardner, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis. 2013;207:306–318.
-
(2013)
J Infect Dis
, vol.207
, pp. 306-318
-
-
Ebihara, H.1
Zivcec, M.2
Gardner, D.3
-
9
-
-
0036094058
-
Evaluation in nonhuman primates of vaccines against Ebola virus
-
T.W.Geisbert, P.Pushko, K.Anderson, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8:503–507.
-
(2002)
Emerg Infect Dis
, vol.8
, pp. 503-507
-
-
Geisbert, T.W.1
Pushko, P.2
Anderson, K.3
-
10
-
-
0029686711
-
Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis
-
E.Ryabchikova, L.Kolesnikova, M.Smolina, et al. Ebola virus infection in guinea pigs:presumable role of granulomatous inflammation in pathogenesis. Arch Virol. 1996;141:909–921.
-
(1996)
Arch Virol
, vol.141
, pp. 909-921
-
-
Ryabchikova, E.1
Kolesnikova, L.2
Smolina, M.3
-
11
-
-
67449089968
-
Development and characterization of a mouse model for Marburg hemorrhagic fever
-
K.L.Warfield, S.B.Bradfute, J.Wells, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol. 2009;83:6404–6415.
-
(2009)
J Virol
, vol.83
, pp. 6404-6415
-
-
Warfield, K.L.1
Bradfute, S.B.2
Wells, J.3
-
12
-
-
84943268225
-
Modeling the disease course of Zaire ebolavirus infection in the Outbred Guinea Pig
-
R.W.Cross, K.A.Fenton, J.B.Geisbert, et al. Modeling the disease course of Zaire ebolavirus infection in the Outbred Guinea Pig. J Infect Dis. 2015;212(Suppl 2):S305–S315.
-
(2015)
J Infect Dis
, vol.212
, pp. S305-S315
-
-
Cross, R.W.1
Fenton, K.A.2
Geisbert, J.B.3
-
13
-
-
0032907635
-
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
-
S.Baize, E.M.Leroy, M.C.Georges-Courbot, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5:423–426.
-
(1999)
Nat Med
, vol.5
, pp. 423-426
-
-
Baize, S.1
Leroy, E.M.2
Georges-Courbot, M.C.3
-
14
-
-
0034006617
-
Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
-
T.W.Geisbert, L.E.Hensley, T.R.Gibb, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80:171–186.
-
(2000)
Lab Invest
, vol.80
, pp. 171-186
-
-
Geisbert, T.W.1
Hensley, L.E.2
Gibb, T.R.3
-
15
-
-
38449094420
-
Lymphocyte death in a mouse model of Ebola virus infection
-
S.B.Bradfute, D.R.Braun, J.D.Shamblin, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis. 2007;196(Suppl 2):S296–S304.
-
(2007)
J Infect Dis
, vol.196
, pp. S296-S304
-
-
Bradfute, S.B.1
Braun, D.R.2
Shamblin, J.D.3
-
16
-
-
64749097604
-
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
-
N.J.Sullivan, J.E.Martin, B.S.Graham, et al. Correlates of protective immunity for Ebola vaccines:implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393–400.
-
(2009)
Nat Rev Microbiol
, vol.7
, pp. 393-400
-
-
Sullivan, N.J.1
Martin, J.E.2
Graham, B.S.3
-
17
-
-
84943270748
-
Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection
-
T.W.Geisbert, J.E.Strong, H.Feldmann. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis. 2015;212(Suppl 2):S91–S97.
-
(2015)
J Infect Dis
, vol.212
, pp. S91-S97
-
-
Geisbert, T.W.1
Strong, J.E.2
Feldmann, H.3
-
18
-
-
84951098598
-
Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material
-
J.C.Trefry, S.E.Wollen, F.Nasar, et al. Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material. Viruses. 2015;7:6739–6754.
-
(2015)
Viruses
, vol.7
, pp. 6739-6754
-
-
Trefry, J.C.1
Wollen, S.E.2
Nasar, F.3
-
19
-
-
84904199045
-
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop
-
R.Hirschberg, L.A.Ward, N.Kilgore, et al. Challenges, progress, and opportunities:proceedings of the filovirus medical countermeasures workshop. Viruses. 2014;6:2673–2697.
-
(2014)
Viruses
, vol.6
, pp. 2673-2697
-
-
Hirschberg, R.1
Ward, L.A.2
Kilgore, N.3
-
20
-
-
38449100363
-
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge
-
K.L.Warfield, D.L.Swenson, G.G.Olinger, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007;196(Suppl 2):S430–S437.• First study demonstrating efficacy of the VLP vaccine in NHPs.
-
(2007)
J Infect Dis
, vol.196
, pp. S430-S437
-
-
Warfield, K.L.1
Swenson, D.L.2
Olinger, G.G.3
-
21
-
-
84925970450
-
Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles
-
K.L.Warfield, J.M.Dye, J.B.Wells, et al. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One. 2015;10:e0118881.
-
(2015)
PLoS One
, vol.10
, pp. e0118881
-
-
Warfield, K.L.1
Dye, J.M.2
Wells, J.B.3
-
22
-
-
84928383358
-
Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates
-
A.Marzi, P.Halfmann, L.Hill-Batorski, et al. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science. 2015;348:439–442.• First study showing efficacy of the ZEBOVΔVP30 vaccine in NHPs.
-
(2015)
Science
, vol.348
, pp. 439-442
-
-
Marzi, A.1
Halfmann, P.2
Hill-Batorski, L.3
-
23
-
-
84876306476
-
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus
-
A.S.Herbert, A.I.Kuehne, J.F.Barth, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013;87:4952–4964.
-
(2013)
J Virol
, vol.87
, pp. 4952-4964
-
-
Herbert, A.S.1
Kuehne, A.I.2
Barth, J.F.3
-
24
-
-
84944458438
-
Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges
-
R.J.Grant-Klein, L.A.Altamura, C.V.Badger, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother. 2015;11:1991–2004.
-
(2015)
Hum Vaccin Immunother
, vol.11
, pp. 1991-2004
-
-
Grant-Klein, R.J.1
Altamura, L.A.2
Badger, C.V.3
-
25
-
-
0034735774
-
Development of a preventive vaccine for Ebola virus infection in primates
-
N.J.Sullivan, A.Sanchez, P.E.Rollin, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–609.• Introduces the first vaccine protective against ZEBOV in NHPs.
-
(2000)
Nature
, vol.408
, pp. 605-609
-
-
Sullivan, N.J.1
Sanchez, A.2
Rollin, P.E.3
-
26
-
-
0042739176
-
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
-
N.J.Sullivan, T.W.Geisbert, J.B.Geisbert, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424:681–684.
-
(2003)
Nature
, vol.424
, pp. 681-684
-
-
Sullivan, N.J.1
Geisbert, T.W.2
Geisbert, J.B.3
-
27
-
-
84907263544
-
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
-
D.A.Stanley, A.N.Honko, C.Asiedu, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–1129.• First study demonstrating efficacy of the ChAd3 vaccine in NHPs.
-
(2014)
Nat Med
, vol.20
, pp. 1126-1129
-
-
Stanley, D.A.1
Honko, A.N.2
Asiedu, C.3
-
28
-
-
84958213109
-
Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
-
A.Marzi, A.A.Murphy, F.Feldmann, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep. 2016;6:21674.• First study demonstrating efficacy of the CMV-based vaccine in NHPs.
-
(2016)
Sci Rep
, vol.6
, pp. 21674
-
-
Marzi, A.1
Murphy, A.A.2
Feldmann, F.3
-
29
-
-
84938719389
-
Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
-
M.Meyer, T.Garron, N.M.Lubaki, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015;125:3241–3255.• First study demonstrating efficacy of the HPIV3 vaccine in NHPs.
-
(2015)
J Clin Invest
, vol.125
, pp. 3241-3255
-
-
Meyer, M.1
Garron, T.2
Lubaki, N.M.3
-
30
-
-
22544441308
-
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
-
S.M.Jones, H.Feldmann, U.Stroher, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–790.• First study showing efficacy of the rVSV–ZEBOV vaccine in NHPs.
-
(2005)
Nat Med
, vol.11
, pp. 786-790
-
-
Jones, S.M.1
Feldmann, H.2
Stroher, U.3
-
31
-
-
84940172223
-
EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain
-
A.Marzi, S.J.Robertson, E.Haddock, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349:739–742.
-
(2015)
Science
, vol.349
, pp. 739-742
-
-
Marzi, A.1
Robertson, S.J.2
Haddock, E.3
-
32
-
-
84878520300
-
Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine
-
J.E.Blaney, A.Marzi, M.Willet, et al. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013;9:e1003389.• First study showing efficacy of the RABV vaccine in NHPs.
-
(2013)
PLoS Pathog
, vol.9
, pp. e1003389
-
-
Blaney, J.E.1
Marzi, A.2
Willet, M.3
-
33
-
-
0035031534
-
Ebola virus VP40-induced particle formation and association with the lipid bilayer
-
L.D.Jasenosky, G.Neumann, I.Lukashevich, et al. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol. 2001;75:5205–5214.
-
(2001)
J Virol
, vol.75
, pp. 5205-5214
-
-
Jasenosky, L.D.1
Neumann, G.2
Lukashevich, I.3
-
34
-
-
3142710288
-
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles
-
J.M.Licata, R.F.Johnson, Z.Han, et al. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol. 2004;78:7344–7351.
-
(2004)
J Virol
, vol.78
, pp. 7344-7351
-
-
Licata, J.M.1
Johnson, R.F.2
Han, Z.3
-
35
-
-
80054771708
-
Advances in virus-like particle vaccines for filoviruses
-
K.L.Warfield, M.J.Aman. Advances in virus-like particle vaccines for filoviruses. J Infect Dis. 2011;204(Suppl 3):S1053–S1059.
-
(2011)
J Infect Dis
, vol.204
, pp. S1053-S1059
-
-
Warfield, K.L.1
Aman, M.J.2
-
37
-
-
84877031340
-
Human papillomavirus vaccines–immune responses
-
M.Stanley, L.A.Pinto, C.Trimble. Human papillomavirus vaccines–immune responses. Vaccine. 2012;30(Suppl 5):F83–F87.
-
(2012)
Vaccine
, vol.30
, pp. F83-F87
-
-
Stanley, M.1
Pinto, L.A.2
Trimble, C.3
-
39
-
-
0032551189
-
DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge
-
L.Vanderzanden, M.Bray, D.Fuller, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246:134–144.
-
(1998)
Virology
, vol.246
, pp. 134-144
-
-
Vanderzanden, L.1
Bray, M.2
Fuller, D.3
-
40
-
-
10744230259
-
Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus
-
J.Riemenschneider, A.Garrison, J.Geisbert, et al. Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003;21:4071–4080.
-
(2003)
Vaccine
, vol.21
, pp. 4071-4080
-
-
Riemenschneider, J.1
Garrison, A.2
Geisbert, J.3
-
41
-
-
0034575944
-
Adenovirus vectors for human gene therapy
-
M.M.Hitt, F.L.Graham. Adenovirus vectors for human gene therapy. Adv Virus Res. 2000;55:479–505.
-
(2000)
Adv Virus Res
, vol.55
, pp. 479-505
-
-
Hitt, M.M.1
Graham, F.L.2
-
42
-
-
84875525572
-
Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates
-
J.S.Richardson, S.Pillet, A.J.Bello, et al. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol. 2013;87:3668–3677.
-
(2013)
J Virol
, vol.87
, pp. 3668-3677
-
-
Richardson, J.S.1
Pillet, S.2
Bello, A.J.3
-
43
-
-
77954057355
-
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species
-
L.E.Hensley, S.Mulangu, C.Asiedu, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 2010;6:e1000904.
-
(2010)
PLoS Pathog
, vol.6
, pp. e1000904
-
-
Hensley, L.E.1
Mulangu, S.2
Asiedu, C.3
-
44
-
-
73949160519
-
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials
-
T.C.Mast, L.Kierstead, S.B.Gupta, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies:correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950–957.
-
(2010)
Vaccine
, vol.28
, pp. 950-957
-
-
Mast, T.C.1
Kierstead, L.2
Gupta, S.B.3
-
45
-
-
33644821543
-
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus
-
G.P.Kobinger, H.Feldmann, Y.Zhi, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346:394–401.
-
(2006)
Virology
, vol.346
, pp. 394-401
-
-
Kobinger, G.P.1
Feldmann, H.2
Zhi, Y.3
-
46
-
-
56149115867
-
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice
-
M.A.Croyle, A.Patel, K.N.Tran, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3:e3548.
-
(2008)
PLoS One
, vol.3
, pp. e3548
-
-
Croyle, M.A.1
Patel, A.2
Tran, K.N.3
-
47
-
-
80054737077
-
Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs
-
J.S.Richardson, M.C.Abou, K.N.Tran, et al. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis. 2011;204(Suppl 3):S1032–S1042.
-
(2011)
J Infect Dis
, vol.204
, pp. S1032-S1042
-
-
Richardson, J.S.1
Abou, M.C.2
Tran, K.N.3
-
48
-
-
84855424528
-
A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs
-
J.H.Choi, S.C.Schafer, L.Zhang, et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm. 2012;9:156–167.
-
(2012)
Mol Pharm
, vol.9
, pp. 156-167
-
-
Choi, J.H.1
Schafer, S.C.2
Zhang, L.3
-
49
-
-
79955387781
-
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
-
T.W.Geisbert, M.Bailey, L.Hensley, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222–4233.
-
(2011)
J Virol
, vol.85
, pp. 4222-4233
-
-
Geisbert, T.W.1
Bailey, M.2
Hensley, L.3
-
50
-
-
33747369807
-
Generation of an adenoviral vaccine vector based on simian adenovirus 21
-
S.Roy, Y.Zhi, G.P.Kobinger, et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol. 2006;87:2477–2485.
-
(2006)
J Gen Virol
, vol.87
, pp. 2477-2485
-
-
Roy, S.1
Zhi, Y.2
Kobinger, G.P.3
-
51
-
-
39549107344
-
Generation of biologically contained Ebola viruses
-
P.Halfmann, J.H.Kim, H.Ebihara, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci U S A. 2008;105:1129–1133.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 1129-1133
-
-
Halfmann, P.1
Kim, J.H.2
Ebihara, H.3
-
52
-
-
0033940077
-
Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
-
A.P.Durbin, M.H.Skiadopoulos, J.M.McAuliffe, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol. 2000;74:6821–6831.
-
(2000)
J Virol
, vol.74
, pp. 6821-6831
-
-
Durbin, A.P.1
Skiadopoulos, M.H.2
McAuliffe, J.M.3
-
53
-
-
0038586407
-
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants
-
R.A.Karron, R.B.Belshe, P.F.Wright, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J. 2003;22:394–405.
-
(2003)
Pediatr Infect Dis J
, vol.22
, pp. 394-405
-
-
Karron, R.A.1
Belshe, R.B.2
Wright, P.F.3
-
54
-
-
34249946893
-
Successful topical respiratory tract immunization of primates against Ebola virus
-
A.Bukreyev, P.E.Rollin, M.K.Tate, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007;81:6379–6388.
-
(2007)
J Virol
, vol.81
, pp. 6379-6388
-
-
Bukreyev, A.1
Rollin, P.E.2
Tate, M.K.3
-
55
-
-
77249161128
-
Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic
-
A.A.Bukreyev, J.M.Dinapoli, L.Yang, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010;399:290–298.
-
(2010)
Virology
, vol.399
, pp. 290-298
-
-
Bukreyev, A.A.1
Dinapoli, J.M.2
Yang, L.3
-
56
-
-
0037213927
-
Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic
-
J.P.McGettigan, R.J.Pomerantz, C.A.Siler, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003;77:237–244.
-
(2003)
J Virol
, vol.77
, pp. 237-244
-
-
McGettigan, J.P.1
Pomerantz, R.J.2
Siler, C.A.3
-
57
-
-
80055058700
-
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
-
J.E.Blaney, C.Wirblich, A.B.Papaneri, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011;85:10605–10616.
-
(2011)
J Virol
, vol.85
, pp. 10605-10616
-
-
Blaney, J.E.1
Wirblich, C.2
Papaneri, A.B.3
-
58
-
-
84943247429
-
Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses
-
M.Willet, D.Kurup, A.Papaneri, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis. 2015;212(Suppl 2):S414–S424.
-
(2015)
J Infect Dis
, vol.212
, pp. S414-S424
-
-
Willet, M.1
Kurup, D.2
Papaneri, A.3
-
59
-
-
0032897970
-
Attenuated vesicular stomatitis viruses as vaccine vectors
-
A.Roberts, L.Buonocore, R.Price, et al. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999;73:3723–3732.
-
(1999)
J Virol
, vol.73
, pp. 3723-3732
-
-
Roberts, A.1
Buonocore, L.2
Price, R.3
-
60
-
-
0034467097
-
Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
-
N.F.Rose, A.Roberts, L.Buonocore, et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74:10903–10910.
-
(2000)
J Virol
, vol.74
, pp. 10903-10910
-
-
Rose, N.F.1
Roberts, A.2
Buonocore, L.3
-
61
-
-
17944369239
-
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
-
N.F.Rose, P.A.Marx, A.Luckay, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106:539–549.
-
(2001)
Cell
, vol.106
, pp. 539-549
-
-
Rose, N.F.1
Marx, P.A.2
Luckay, A.3
-
62
-
-
84870601170
-
Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections
-
2157-2526-S1-004
-
A.Marzi, H.Feldmann, T.W.Geisbert, et al. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef. 2011;S1(4):pii:2157-2526-S1-004.
-
(2011)
J Bioterror Biodef
, vol.S1
, Issue.4
-
-
Marzi, A.1
Feldmann, H.2
Geisbert, T.W.3
-
63
-
-
84859181562
-
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates
-
C.E.Mire, A.D.Miller, A.Carville, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6:e1567.
-
(2012)
PLoS Negl Trop Dis
, vol.6
, pp. e1567
-
-
Mire, C.E.1
Miller, A.D.2
Carville, A.3
-
64
-
-
2342455182
-
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses
-
M.Garbutt, R.Liebscher, V.Wahl-Jensen, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78:5458–5465.
-
(2004)
J Virol
, vol.78
, pp. 5458-5465
-
-
Garbutt, M.1
Liebscher, R.2
Wahl-Jensen, V.3
-
65
-
-
84929511906
-
A recombinant vesicular stomatitis virus Ebola vaccine – preliminary report
-
J.A.Regules, J.H.Beigel, K.M.Paolino, et al. A recombinant vesicular stomatitis virus Ebola vaccine – preliminary report. N Engl J Med. 2015. [Epub ahead of print].
-
(2015)
N Engl J Med
-
-
Regules, J.A.1
Beigel, J.H.2
Paolino, K.M.3
-
66
-
-
84964969174
-
Phase 1 trials of rVSV Ebola vaccine in Africa and Europe – preliminary report
-
S.T.Agnandji, A.Huttner, M.E.Zinser, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe – preliminary report. N Engl J Med. 2015;374:1647–1660.
-
(2015)
N Engl J Med
, vol.374
, pp. 1647-1660
-
-
Agnandji, S.T.1
Huttner, A.2
Zinser, M.E.3
-
67
-
-
84940952795
-
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
-
A.M.Henao-Restrepo, I.M.Longini, M.Egger, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein:interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–866.• First study demonstrating efficacy of the rVSV–ZEBOV vaccine in humans.
-
(2015)
Lancet
, vol.386
, pp. 857-866
-
-
Henao-Restrepo, A.M.1
Longini, I.M.2
Egger, M.3
-
68
-
-
84928792708
-
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus
-
C.E.Mire, D.Matassov, J.B.Geisbert, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015;520:688–691.
-
(2015)
Nature
, vol.520
, pp. 688-691
-
-
Mire, C.E.1
Matassov, D.2
Geisbert, J.B.3
-
69
-
-
56649099057
-
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
-
T.W.Geisbert, K.M.Daddario-Dicaprio, J.B.Geisbert, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26:6894–6900.
-
(2008)
Vaccine
, vol.26
, pp. 6894-6900
-
-
Geisbert, T.W.1
Daddario-Dicaprio, K.M.2
Geisbert, J.B.3
-
70
-
-
65849373288
-
Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses
-
X.Qiu, L.Fernando, J.B.Alimonti, et al. Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One. 2009;4:e5547.
-
(2009)
PLoS One
, vol.4
, pp. e5547
-
-
Qiu, X.1
Fernando, L.2
Alimonti, J.B.3
-
71
-
-
84873202509
-
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates
-
A.Marzi, F.Engelmann, F.Feldmann, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–1898.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 1893-1898
-
-
Marzi, A.1
Engelmann, F.2
Feldmann, F.3
-
72
-
-
80054753979
-
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy
-
A.Marzi, H.Ebihara, J.Callison, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011;204(Suppl 3):S1066–S1074.
-
(2011)
J Infect Dis
, vol.204
, pp. S1066-S1074
-
-
Marzi, A.1
Ebihara, H.2
Callison, J.3
-
73
-
-
67650383786
-
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
-
T.W.Geisbert, J.B.Geisbert, A.Leung, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83:7296–7304.
-
(2009)
J Virol
, vol.83
, pp. 7296-7304
-
-
Geisbert, T.W.1
Geisbert, J.B.2
Leung, A.3
-
74
-
-
84892698411
-
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus
-
C.E.Mire, J.B.Geisbert, A.Marzi, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7:e2600.
-
(2013)
PLoS Negl Trop Dis
, vol.7
, pp. e2600
-
-
Mire, C.E.1
Geisbert, J.B.2
Marzi, A.3
-
75
-
-
57149112519
-
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
-
T.W.Geisbert, K.M.Daddario-Dicaprio, M.G.Lewis, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:e1000225.
-
(2008)
PLoS Pathog
, vol.4
, pp. e1000225
-
-
Geisbert, T.W.1
Daddario-Dicaprio, K.M.2
Lewis, M.G.3
-
76
-
-
84924943114
-
Safety of recombinant VSV-Ebola virus vaccine vector in pigs
-
E.De Wit, A.Marzi, T.Bushmaker, et al. Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis. 2015;21:702–704.
-
(2015)
Emerg Infect Dis
, vol.21
, pp. 702-704
-
-
De Wit, E.1
Marzi, A.2
Bushmaker, T.3
-
77
-
-
33846909686
-
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
-
J.E.Martin, N.J.Sullivan, M.E.Enama, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–1277.
-
(2006)
Clin Vaccine Immunol
, vol.13
, pp. 1267-1277
-
-
Martin, J.E.1
Sullivan, N.J.2
Enama, M.E.3
-
78
-
-
84922473334
-
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial
-
U.N.Sarwar, P.Costner, M.E.Enama, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211:549–557.
-
(2015)
J Infect Dis
, vol.211
, pp. 549-557
-
-
Sarwar, U.N.1
Costner, P.2
Enama, M.E.3
-
79
-
-
84928423301
-
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
-
H.Kibuuka, N.M.Berkowitz, M.Millard, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults:a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015;385:1545–1554.
-
(2015)
Lancet
, vol.385
, pp. 1545-1554
-
-
Kibuuka, H.1
Berkowitz, N.M.2
Millard, M.3
-
80
-
-
78649703575
-
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
-
J.E.Ledgerwood, P.Costner, N.Desai, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–313.
-
(2010)
Vaccine
, vol.29
, pp. 304-313
-
-
Ledgerwood, J.E.1
Costner, P.2
Desai, N.3
-
81
-
-
84934286956
-
Safety and immunogenicity of a nocel recombinant adenovirus type 5 vector based Ebola vaccine in healthyadults in China: preliminary report of a phase 1, randomized, double-blind, placebo-controlled clinical trial
-
F.-C.Zhu, L.-H.Hou, J.-X.Li, et al. Safety and immunogenicity of a nocel recombinant adenovirus type 5 vector based Ebola vaccine in healthyadults in China:preliminary report of a phase 1, randomized, double-blind, placebo-controlled clinical trial. Lancet. 2015;385:2272–2279.
-
(2015)
Lancet
, vol.385
, pp. 2272-2279
-
-
Zhu, F.-C.1
Hou, L.-H.2
Li, J.-X.3
-
82
-
-
84983215000
-
Chimpanzee adenovirus vector Ebola vaccine – preliminary report
-
J.E.Ledgerwood, A.D.DeZure, D.A.Stanley, et al. Chimpanzee adenovirus vector Ebola vaccine – preliminary report. N Engl J Med. 2015;373:775–776.
-
(2015)
N Engl J Med
, vol.373
, pp. 775-776
-
-
Ledgerwood, J.E.1
DeZure, A.D.2
Stanley, D.A.3
-
83
-
-
84959245846
-
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
-
O.De Santis, R.Audran, E.Pothin, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults:a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2015;16:311–320.
-
(2015)
Lancet Infect Dis
, vol.16
, pp. 311-320
-
-
De Santis, O.1
Audran, R.2
Pothin, E.3
-
84
-
-
84959184825
-
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
-
M.D.Tapia, S.O.Sow, K.E.Lyke, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.
-
(2016)
Lancet Infect Dis
, vol.16
, pp. 31-42
-
-
Tapia, M.D.1
Sow, S.O.2
Lyke, K.E.3
-
85
-
-
84942194673
-
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
-
A.Huttner, J.-A.Dayer, S.Yerly, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine:a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156–1166.
-
(2015)
Lancet Infect Dis
, vol.15
, pp. 1156-1166
-
-
Huttner, A.1
Dayer, J.-A.2
Yerly, S.3
-
86
-
-
84908457744
-
Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents
-
G.Wong, J.Audet, L.Fernando, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014;32:5722–5729.
-
(2014)
Vaccine
, vol.32
, pp. 5722-5729
-
-
Wong, G.1
Audet, J.2
Fernando, L.3
-
87
-
-
84880310429
-
Vaccines for viral hemorrhagic fevers–progress and shortcomings
-
D.Falzarano, H.Feldmann. Vaccines for viral hemorrhagic fevers–progress and shortcomings. Curr Opin Virol. 2013;3:343–351.
-
(2013)
Curr Opin Virol
, vol.3
, pp. 343-351
-
-
Falzarano, D.1
Feldmann, H.2
-
88
-
-
84936940562
-
Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera
-
M.E.B.Jones, A.J.Schuh, B.R.Amman, et al. Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera. Viruses. 2015;7:3420–3442.
-
(2015)
Viruses
, vol.7
, pp. 3420-3442
-
-
Jones, M.E.B.1
Schuh, A.J.2
Amman, B.R.3
-
89
-
-
0036547563
-
Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis)
-
A.Vos, E.Pommerening, L.Neubert, et al. Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis). J Wildl Dis. 2002;38:428–431.
-
(2002)
J Wildl Dis
, vol.38
, pp. 428-431
-
-
Vos, A.1
Pommerening, E.2
Neubert, L.3
|